{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T04:14:45Z","timestamp":1742098485972,"version":"3.38.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jdiacomp.2024.108905","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T17:13:18Z","timestamp":1730999598000},"page":"108905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cilostazol for the treatment of distal symmetrical polyneuropathy in diabetes mellitus: Where do we stand?"],"prefix":"10.1016","volume":"38","author":[{"given":"Dimitrios","family":"Pantazopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evanthia","family":"Gouveri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2024.108905_bb0005","doi-asserted-by":"crossref","first-page":"390","DOI":"10.21037\/apm-22-693","article-title":"Diabetic peripheral neuropathy essentials: a narrative review","volume":"12","author":"Chang","year":"2023","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110764","article-title":"Pathogenetic treatments for diabetic peripheral neuropathy","volume":"206","author":"Ziegler","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0015","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/brain\/awab079","article-title":"Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management","volume":"144","author":"Jensen","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/2047487319881021","article-title":"The global epidemics of diabetes in the 21st century: current situation and perspectives","volume":"26","author":"Standl","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.748193","article-title":"Advances about immunoinflammatory pathogenesis and treatment in diabetic peripheral neuropathy","volume":"12","author":"Xue","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-019-0092-1","volume":"5","author":"Feldman","year":"2019","journal-title":"Diabetic neuropathy Nat Rev Dis Primers"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1210\/er.2018-00107","article-title":"Emerging biomarkers, tools, and treatments for diabetic polyneuropathy","volume":"40","author":"B\u00f6nhof","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2337\/dci22-0043","article-title":"Etiology, epidemiology, and disparities in the burden of diabetic foot ulcers","volume":"46","author":"McDermott","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112717","article-title":"Progress in the treatment of diabetic peripheral neuropathy","volume":"148","author":"Yang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0050","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/0003319711402664","article-title":"Cilostazol in diabetic neuropathy: premature farewell or new beginning?","volume":"62","author":"Papanas","year":"2011","journal-title":"Angiology"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0055","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.lfs.2018.02.038","article-title":"Cilostazol alleviates streptozotocin-induced testicular injury in rats via PI3K\/Akt pathway","volume":"198","author":"Mohamed","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107336","article-title":"Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target","volume":"92","author":"Motta","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154867","article-title":"Management of diabetic neuropathy","volume":"123","author":"Cernea","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0070","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.3390\/nu14153086","article-title":"Advanced glycation end products and their effect on vascular complications in type 2 diabetes mellitus","volume":"14","author":"Lee","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0075","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1194\/jlr.M021188","article-title":"Diabetes-induced myelin abnormalities are associated with an altered lipid pattern: protective effects of LXR activation","volume":"53","author":"Cermenati","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0080","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s12035-016-9702-z","article-title":"Association between tumor necrosis factor-\u03b1 and diabetic peripheral neuropathy in patients with type 2 diabetes: a meta-analysis","volume":"54","author":"Mu","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0085","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/jdi.12833","article-title":"Diabetic neuropathy and the sensory neuron: new aspects of pathogenesis and their treatment implications","volume":"9","author":"Kobayashi","year":"2018","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/endrev\/bnaa025","article-title":"Microvascular dysfunction in diabetes mellitus and cardiometabolic disease","volume":"42","author":"Horton","year":"2021","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0095","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrneurol.2016.201","article-title":"Schwann cell interactions with axons and microvessels in diabetic neuropathy","volume":"13","author":"Gon\u00e7alves","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0100","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s001250050708","article-title":"Association of diabetic neuropathy with Na\/K ATPase gene polymorphism","volume":"40","author":"Vague","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0105","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0168-8227(95)01184-6","article-title":"Effects of cilostazol on development of experimental diabetic neuropathy: functional and structural studies, and Na+ -K+ -ATPase acidity in peripheral nerve in rats with streptozotocin-induced diabetes","volume":"30","author":"Naka","year":"1995","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0110","first-page":"37","article-title":"C-peptide, Na+,K(+)-ATPase, and diabetes","volume":"5","author":"Vague","year":"2004","journal-title":"Exp Diabesity Res"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0115","article-title":"Cilostazol for intermittent claudication","volume":"6(6):CD003748","author":"Brown","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0120","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/iwj.12085","article-title":"Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease","volume":"12","author":"de Franciscis","year":"2015","journal-title":"Int. Wound J."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0125","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0021-9150(99)00480-3","article-title":"Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats","volume":"152","author":"Tani","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0130","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1080\/14656566.2018.1515199","article-title":"Cilostazol for treatment of cerebral infarction","volume":"19","author":"Noma","year":"2018","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0135","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/1074248414545126","article-title":"Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data?","volume":"20","author":"Azarbal","year":"2015","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosissup.2005.09.002","article-title":"Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding","volume":"6","author":"Goto","year":"2005","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0145","unstructured":"Cilostazol [package insert]. Silver Spring, MD: U.S. Food and Drug Administration; 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020863s024lbl.pdf. Accessed May 26, 2024."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0150","unstructured":"Cilostazol-containing medicines. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/cilostazol-containing-medicines. Accessed May 26, 2024."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0155","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10557-021-07187-x","article-title":"Cilostazol: a review of basic mechanisms and clinical uses","volume":"36","author":"Kherallah","year":"2022","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0160","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: phosphodiesterase inhibitors","volume":"72","author":"Gresele","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0165","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/01.RES.0000256354.95791.f1","article-title":"Overview of PDEs and their regulation","volume":"100","author":"Omori","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0170","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12020-017-1279-4","article-title":"Effect of cilostazol in treating diabetes-associated microvascular complications","volume":"56","author":"Asal","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0175","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1161\/STROKEAHA.121.035002","article-title":"Cilostazol for secondary stroke prevention: history, evidence, limitations, and possibilities","volume":"52","author":"de Havenon","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0180","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S0002-9149(02)02869-2","article-title":"Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication","volume":"90","author":"Thompson","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0185","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1053\/j.ajkd.2012.02.340","article-title":"Peripheral artery disease and CKD: a focus on peripheral artery disease as a critical component of CKD care","volume":"60","author":"Garimella","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0190","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2459\/JCM.0b013e3283439746","article-title":"Effects of cilostazol in the heart","volume":"12","author":"Kanlop","year":"2011","journal-title":"J. Cardiovasc. Med. (Hagerstown)"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108514","article-title":"Cilostazol is an effective causal therapy for preventing paclitaxel-induced peripheral neuropathy by suppression of Schwann cell dedifferentiation","volume":"188","author":"Koyanagi","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0200","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/BF00400579","article-title":"Effect of cilostazol on experimental diabetic neuropathy in the rat","volume":"38","author":"Kihara","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0205","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1056-8727(96)00023-2","article-title":"Effects of cilostazol on the peripheral nerve function and structure in STZ-induced diabetic rats","volume":"11","author":"Uehara","year":"1997","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0210","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0014-2999(98)00356-2","article-title":"Effects of cilostazol, an antiplatelet agent, on axonal regeneration following nerve injury in diabetic rats","volume":"352","author":"Yamamoto","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0215","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0014-4886(85)90016-0","article-title":"Ornithine decarboxylase in motoneurons during regeneration","volume":"89","author":"Tetzlaff","year":"1985","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0220","doi-asserted-by":"crossref","first-page":"14529","DOI":"10.1074\/jbc.R500031200","article-title":"Regulation of ornithine decarboxylase","volume":"281","author":"Pegg","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0225","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3904\/kjim.1999.14.2.34","article-title":"Effect of cilostazol on the neuropathies of streptozotocin-induced diabetic rats","volume":"14","author":"Suh","year":"1999","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.771271","article-title":"Cilostazol ameliorates peripheral neuropathic pain in streptozotocin-induced type \u0399 diabetic rats","volume":"12","author":"Cheng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0235","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3390\/medicina59030553","article-title":"Peripheral nerve denervation in streptozotocin-induced diabetic rats is reduced by cilostazol","volume":"59","author":"Tseng","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0240","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/j.1476-5381.2009.00615.x","article-title":"Cilostazol is anti-inflammatory in BV2 microglial cells by inactivating nuclear factor-kappaB and inhibiting mitogen-activated protein kinases","volume":"159","author":"Jung","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0245","doi-asserted-by":"crossref","first-page":"7847","DOI":"10.3390\/ijms25147847","article-title":"Cilostazol ameliorates motor dysfunction and schwann cell impairment in streptozotocin-induced diabetic rats","volume":"25","author":"Chang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0250","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/0003319708321100","article-title":"The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease","volume":"59","author":"O\u2019Donnell","year":"2008","journal-title":"Angiology"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0255","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/0003319711410594","article-title":"Cilostazol: a pilot study on safety and clinical efficacy in neuropathies of diabetes mellitus type 2 (ASCEND)","volume":"62","author":"Rosales","year":"2011","journal-title":"Angiology"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0260","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdi.13401","article-title":"Current concepts in the management of diabetic polyneuropathy","volume":"12","author":"Ziegler","year":"2021","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0265","first-page":"461","article-title":"Randomized, double-blind, controlled trial of a combination of alpha-lipoic acid and pregabalin for neuropathic pain: the PAIN-CARE trial","volume":"165","author":"Gilron","year":"2024","journal-title":"Pain"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0270","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.2174\/1871530320666200506081407","article-title":"Oral alpha lipoic acid treatment for symptomatic diabetic peripheral neuropathy: a randomized double-blinded placebo-controlled study","volume":"20","author":"El-Nahas","year":"2020","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0275","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/cts.12977","article-title":"Gene therapy for diabetic peripheral neuropathy: a randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor","volume":"14","author":"Kessler","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jdiacomp.2024.108905_bb0280","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/phar.2830","article-title":"Effect of cilostazol on preventing paclitaxel-induced neuropathy in patients with breast cancer: a randomized controlled trial","volume":"43","author":"Haroun","year":"2023","journal-title":"Pharmacotherapy"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872724002319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872724002319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T11:15:20Z","timestamp":1742037320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872724002319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1056872724002319"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108905","relation":{},"ISSN":["1056-8727"],"issn-type":[{"type":"print","value":"1056-8727"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cilostazol for the treatment of distal symmetrical polyneuropathy in diabetes mellitus: Where do we stand?","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108905"}}